source
- AstraZeneca drops two early-phase prostate cancer programsAstraZeneca announced it is terminating development of two early-phase prostate cancer candidates, AZD9750 and AZD8359, as part of a quarterly pipeline review. AZD9750, an oral androgen-receptor d…
- Bambusa Therapeutics exceeds IPO target raising $169 million, while Aspen Neuroscience falls short with $141 millionBambusa Therapeutics announced that its initial public offering was upsized, selling more shares at the midpoint of its $15‑$17 range and raising about $168.9 million, exceeding the $150.4 million…